Clinical resource
Hepatic metastases stereotactic EBRT (eviQ ID 4026)
eviQ, Cancer Institute NSW
DoseLab summary
Endorsed eviQ protocol for stereotactic treatment of liver metastases in three or five fractions (three preferred when organ limits allow). Its organ table gives a separate column for each fraction count. Patients with cirrhosis are treated as for hepatocellular carcinoma under the companion primary-liver protocol.
Why this is useful
A liver-metastasis SBRT protocol with separate 3- and 5-fraction organ columns, each value credited to the LARK protocol, the UK 2022 SABR consensus or the chest wall literature.
Reference details
- Title
- Hepatic metastases stereotactic EBRT (eviQ ID 4026)
- Authors / organization
- eviQ, Cancer Institute NSW
- Publication / protocol
- eviQ Radiation Oncology protocol 4026
- Version
- v.4 — last reviewed 28 October 2025; review due 30 June 2028
- Year
- 2025
- DOI
- Pending verification
- Disease sites
- GI
- Topics
- Liver, SBRT, Liver metastases, Dose Constraints, Protocols
- Fractionation context
- 42–54 Gy / 3 fx or 40–60 Gy / 5 fx
- Last reviewed by DoseLab
- 2026-09-29